The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e. those impacting fewer than 200,000 people in the United Statesii. These benefits include market exclusivity, financial incentives, regulatory assistance, and support with drug development. Overall, the designation incentivizes and supports the development of certain

TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is honored to welcome Professor Teodoro Forcht Dagi, a renowned neurosurgeon, life science

NurExone has created ExoTherapy, a cutting-edge exosome-based drug-delivery platform, and is currently developing its lead product, ExoPTEN, as a novel therapy for acute spinal cord injuries.   Read More >>>

The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market. This endeavor combines Inteligex’s established expertise in stem cell treatments with NurExone’s ExoTherapy drug delivery platform. Currently, NurExone is in the process of developing

A Pre-IND meeting offers open communication between applicants and the FDA, enabling the applicants to receive information regarding the preparation of an IND application and guidance for the clinical studies of the Company’s ExoPTEN drug. The FDA provided clear and valuable guidance on the chemistry manufacturing and controls and agreed

“I am pleased with the outcome of our Private Placement and on behalf of NurExone’s team, I would like to thank our investors and shareholders for the support and trust in the Company and its team”, said Dr. Lior Shaltiel, CEO of NurExone. Read More >>>

“The Company continues to achieve key milestones for our prospective ExoPTEN drug and the development of an exosome-based therapy platform to be potentially used to achieve functional recovery in acute injuries related to the central nervous system,” said Dr. Lior Shaltiel, CEO of NurExone. “We believe that the advancements made